Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells 14,000 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Kiniksa Pharmaceuticals Stock Performance

KNSA opened at $18.54 on Friday. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -132.42 and a beta of 0.29. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15. The business’s fifty day moving average is $20.67 and its two-hundred day moving average is $23.21.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.20) EPS. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Essex Investment Management Co. LLC raised its position in shares of Kiniksa Pharmaceuticals by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after purchasing an additional 717 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after acquiring an additional 1,100 shares during the last quarter. CWM LLC lifted its position in shares of Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at $50,000. Finally, Bank of New York Mellon Corp increased its position in Kiniksa Pharmaceuticals by 2.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company’s stock worth $2,150,000 after purchasing an additional 2,563 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KNSA. JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.